EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma

On August 25, 2020, a marketing authorization valid through the European Union was issued for belantamab mafodotin monotherapy for the treatment of multiple myeloma (MM) in adult patients who have received at least four prior therapies, whose disease is refractory to at least one proteasome inhibito...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Tzogani, Kyriaki, Penttilä, Karri, Lähteenvuo, Johanna, Lapveteläinen, Tuomo, Lopez Anglada, Lucía, Prieto, Carolina, Garcia‐Ochoa, Blanca, Enzmann, Harald, Gisselbrecht, Christian, Delgado, Julio, Pignatti, Francesco
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2020
Matèries:
Regulatory Issues: EMA
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7794172/
https://ncbi.nlm.nih.gov/pubmed/33179377
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13592
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars